



DIMER

Harnessing Therapeutic Potential of Covalent Dimerization

Nikhilesh Singh, PhD Co-Founder and CEO

NCE dimers with expanded therapeutic potential



Platform Technology

- Maximizes site-of-action distribution
- Minimizes off-target negative implications



DMX-101

- Successful Phase 1 & 2 in IBS-D (diarrhea & ab pain)
- Phase 2-ready for chronic pain
- First in class, orally bioavailable, non-addictive opioid



Chronic Pain

- Lower back pain
- Chemo-induced neuropathy
- SCD-adults ▪ IBD-IBS




Financing

- Series A: targeting round up to \$40M
- Phase 2 PoC in chronic pain and IND on 2nd asset

Dimer improves bioavailability and increases site-of-action distribution

DMX-101



Drug

Covalent Linker

Dimer

- Size limits distribution, e.g., DMX-101 no CNS exposure
- Peripheral partial mu agonist/full kappa antagonist to control pain
- Multiple sites of action increase chances of reaching un-druggable sites
- Linker creates chemically and metabolically stable NCE dimer
- Linker capable of forming homodimers or heterodimers

DMX-101 will target peripheral opioid receptors to control pain without CNS exposure

DMX-101 provides efficacy without the risk of addiction, impairment, or development of tolerance


The 7 deadly sins of conventional opioids:

- 1 Lower level of consciousness and cause sedation, drowsiness, sleep disturbance
- 2 Cause cognitive and psychomotor impairment, delirium, hallucinations, nightmares
- 3 Are neurotoxic and precipitate hyperalgesia
- 4 Carry a high risk of addiction, abuse, and misuse, even at therapeutic dose
- 5 Are organ toxic and not safe, i.e., acute pancreatitis
- 6 Lose efficacy even at higher doses after chronic use
- 7 Can cause respiratory depression and death after overdose


DMX-101 cognition-sparing effect was comparable to placebo as the drug did not cross the blood brain barrier

Standardized rodent models

Locomotor Activity after IV Injection




Brain: Blood Ratio after IV Injection




Study numbers AB44258, AB31831 Eurofins

DMX-101 yields high blood levels ($C_{max} > 1000$ ng/mL) with a long half-life but without CNS exposure

Plasma Concentrations Day 7 (Steady State) +/- SE (ng/mL)



Change in Pupillary Diameter (mm) during the Study




Systemic Exposure Benefits Therapeutic Potential

Indicates No Central Opioid Effect

Data source: Study OM-102 Phase 1 Multiple Ascending Dose study

DMX-101: Robust efficacy trend in pain despite limited power (small sample)




Pain Responders

Pain responders are defined as those patients who meet the daily pain response criteria for at least 50% of days with diary entry during the interval, with ≥ 60 days of diary entries over the 12-week interval - target Phase 3 population

Significant improvement in Patient Global Impressions of Change at week 12

Overall Patient Global Impression of Change (PGIC) Score of "Much Improved" (% IBS-D Patients)



Overall Patient Global Impression of Change (PGIC)

Patients were asked to compare their current symptoms to those before beginning treatment using the multiple-choice question, "Compared with the beginning of the study, before you started treatment, your symptoms of IBS-D today are:" [Much worse, Moderately worse, A little worse, Stayed the same, A little improved, Moderately improved, or Much improved] - target Phase 3 population

DIMERx drugs will bring transformational change to standard of care


Program	MOA/Indication	Research	Pre-clinical	Phase 1	Phase 2
DMX-101	GCPR-mediated peripheral mu/kappa Chronic pain	Chronic lower back pain			
		Chemo-induced neuro pain			
		Sickle cell disease			
		IBD-IBS			
DMX-101	Irritable bowel syndrome with diarrhea (IBS-D)	Fast-Track Designation			
DMX-MO	Early stage/confidential Various opportunities				

DIMERx intellectual property footprint is broad and global, extends into 2040s



Series A funds multiple value inflection points

Positive interim analysis triggers multiple strategic options



- Lack of abuse potential
- Phase 2 interim analysis
- Clinical proof of concept
- New IND with new candidate

Management is seeking non-dilutive grant funding to minimize financial risk

Team: Multiple NDAs, raising capital, and value creation



Nikhilesh Singh, PhD
Co-Founder/
CEO

- >25 years industry leadership experience
- Founded OrphoMed, Inc., closing \$43 million Series A financing
- Over 100 patents
- Invented and oversaw the development and approval of Intermezzo®
- Developed patented formulations with unique therapeutic positioning for Vicks® Formula 44® and Nyquil®



Gregory Beyer
Co-Founder/
CFO

- >25 years industry leadership experience
- CFO at OrphoMed, Inc., closing \$43 million Series A financing and \$3M in debt financing
- Senior financial roles at Adamas Pharma, Novacea, Inc., and 3Com Corp.
- Founded Beyer Financial Consulting in 2009 to serve clients in the biotechnology and technology industries



Detlef Albrecht, MD
CMO Consultant

- >30 years industry leadership experience
- Led clinical activities for 7 US NDAs and 5 EU Market authorizations (including Durogesic® D-trans Patch & Electrotransport fentanyl patch; IONSYS®)
- Led or co-led over \$400M in private & public financings (including Satsuma IPO)
- Led building of multiple companies (Ilypsa; Sorbent; Satsuma)



Matthew Pietras
Strategic
Advisor

- >20 years industry leadership experience
- Founded Exon Advisors, fractional CFO services for Life Sciences companies
- Led finance for multiple private/public life sciences companies, raising >\$350M from Seed to PIPE
- CFO and Sr Finance roles at BioCytics, StageZero Life Sciences, CiVi Biopharma, Viela Bio, AstraZeneca, Medimmune, Wells Fargo, Wachovia and KPMG

Board of Directors

In addition to
CEO & CFO

Peter Barton Hutt

Former Chief Counsel at the FDA 1971-1975

Harvinder Dhani

Tech investor with deep social altruistic commitment

Key Scientific Advisors

Lynn Webster, MD

President emeritus, American Pain Society

Maurizio Fava, MD

Academy of Medicine and MGH Chair, Psychiatry

DIMERx primed for success

- DMX-101 de-risked asset
 - 2 significant unmet medical needs
 - Chronic pain
 - IBS-D in patients, with and without gallbladder
- Global patent footprint
- Skilled and experienced team
- High probability of success



DIMER_x

For investment inquiries: greg@dimerx.com

[Pitchbook Profile](#)
